Lack of effect of gliclazide on early diabetic nephropathy and retinopathy: a two-year controlled study.

Abstract

This study has attempted to document a specific haemovascular action of gliclazide on the reversal of early diabetic microangiopathy. A prospective double-blind controlled study was performed over 2 years, comparing gliclazide versus placebo in insulin-treated and gliclazide versus glibenclamide in non-insulin-treated diabetic subjects, after a 1-year run-in period. Glycaemic control was not significantly different in gliclazide- and non-gliclazide-treated subjects before or after the commencement of active therapy. Following treatment with gliclazide in 17/32 insulin-treated and 8/17 non-insulin-treated subjects with Albustix-negative proteinuria, there was no difference in retinopathy score, total proteinuria or the renal clearance of creatinine, albumin, transferrin and immunoglobulin G. In the insulin-treated group, progression of retinopathy was observed in approximately one-third of subjects, but no parameter of proteinuria progressed over 2 years. Thus, this study did not detect a reversal of the parameters measured and does not support an action of gliclazide on diabetic microangiopathy, independent of its hypoglycaemic action.

• Authors: G Jerums, R M Murray, E Seeman, M E Cooper, S Edgley, K Marwick, R G Larkins, T J Martin
• Journal: Diabetes research and clinical practice (Diabetes Res Clin Pract) 1987 Mar-Apr Vol. 3 Issue 2 Pg. 71-80 ISSN: 0168-8227 [Print] Ireland
• PMID: 3552537 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Glycated Hemoglobin A
• Insulin
• Sulfonylurea Compounds
• Creatinine
• Gliclazide

Topics

• Blood Pressure (drug effects)
• Clinical Trials as Topic
• Creatinine (blood)
• Diabetes Complications
• Diabetes Mellitus (drug therapy)
• Diabetic Nephropathies (prevention & control)
• Diabetic Retinopathy (prevention & control)
• Double-Blind Method
• Gliclazide (therapeutic use)
• Glycated Hemoglobin (metabolism)
• Humans
• Insulin (therapeutic use)
• Proteinuria (prevention & control)
• Random Allocation
• Sulfonylurea Compounds (therapeutic use)